An array of precisely directed, cancer-fighting drugs may be on the horizon, thanks to a recent agreement signed between a Maryland-based pharmaceutical company and a company formed by University of Utah researchers.
On Dec. 14, Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential oncology and central nervous system therapeutics, and TheraTarget, Inc., a developer of polymer therapeutics for the treatment of cancer, announced the formation of a joint research collaboration agreement.
Under the terms of the agreement, TheraTarget will synthesize and supply Rexahn with polymer-drug conjugate products, which are part of Rexahn’s polymer-based nanomedicine portfolio. Co-founders of TheraTarget are University of Utah professors Jindrich (Henry) Kopecek and Hamid Ghandehari, who is a USTAR researcher.

Hamid Ghandehari
The class of compounds to be synthesized use technology pioneered by Kopecek. The compounds are composed of chains of polymers, to which anti-cancer drugs are attached. The compounds are able to target cancerous cells, and deliver the cell-killing agents. Because of their high molecular weight, the compounds stay active in the bloodstream longer than conventional pharmaceuticals, thereby enhancing dose efficacy. (more…)